港股異動 | 微創醫療(0853.HK)一度升至8% 擬分拆微創心通上市
格隆匯1月18日丨微創醫療(0853.HK)一度急漲近8%,現報53.2港元,股價有望挑戰新高價。暫成交2.23億港元,總市值962.68億港元。微創醫療公佈,就建議分拆微創心通醫療科技有限公司在聯交所主板獨立上市,微創心通醫療科技有限公司已於2021年1月15日向聯交所遞交聆訊後資料集,並於聯交所網站發佈。據瞭解,公司計劃集資3億美元(約23.4億元)。中金、花旗及摩通為聯席保薦人。公司上市前投資者明星股東雲集,包括CDG、GIC、海通基金、清池資本、高瓴資本等。其中,高瓴持股2.13%,控股股東微創醫療持股50.06%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.